CounterPath (CPAH) Upgraded to “Buy” by Zacks Investment Research
Zacks Investment Research upgraded shares of CounterPath (NASDAQ:CPAH) (TSE:CCV) from a hold rating to a buy rating in a research note issued to investors on Monday. The brokerage currently has $3.00 price target on the software maker’s stock.
According to Zacks, “CounterPath, Corp. focuses on the design, development, marketing and sales of desktop and mobile application software, conferencing server software, gateway server software and related professional services, such as pre and post sales technical support and customization services. The Company’s software products are sold into the telecommunications sector, specifically the voice over Internet protocol, unified communications and fixed-mobile convergence markets. The company’s product suite includes SIP-based softphones, server applications and Fixed Mobile Convergence solutions that enable service providers, enterprises and Original Equipment Manufacturers to cost-effectively integrate voice, video, presence and Instant Messaging applications into their VoIP offerings and extend functionality across both fixed and mobile networks. This company is covered under both TSX and NYSE as V.CCV and CPAH respectively. “
Separately, ValuEngine lowered CounterPath from a hold rating to a sell rating in a research report on Friday, September 1st.
CounterPath Company Profile
CounterPath Corporation designs, develops and sells software and services that enable enterprises and telecommunication service providers to deliver unified communications (UC) services, including voice, video, messaging and collaboration functionality, over their Internet Protocol (IP)-based networks.
Receive News & Ratings for CounterPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CounterPath and related companies with MarketBeat.com's FREE daily email newsletter.